Clinical Bioenergetics. From Pathophysiology to Clinical Translation

Table of Contents

Part I: Foundational aspects of bioenergetics and disease 1. Tissue specificity of energy metabolism in mitochondria 2. Impaired mitochondrial bioenergetics and signaling pathways: an overview

Part II: Disease-specific case studies 3. Abnormal mitochondrial metabolism in obesity and insulin resistance 4. Impaired mitochondrial energy metabolism: etiologies and implications in neurodegenerative disease 5. Mitochondrial dysfunction in kidney diseases 6. Mitochondrial role in NAFLD as a chronic disease 7. Decreased bioenergetics in traumatic brain injury 8. Impaired mitochondrial bioenergetics in psychiatric disorders

Part III: Modes of analysis in clinical bioenergetics 9. Monitoring mitochondrial oxygenation in clinical environment 10. Assessing metabolic flexibility and mitochondrial bioenergetics 11. Assessing the real-time metabolism and bioenergetics of single cells using fluorescence biosensors 12. Bioenergetic profiling in the skin 13. Evaluating tissue bioenergetics by phosphorous-31 magnetic resonance spectroscopy 14. Targeting respiratory complex Idmolecular mechanism and drug design

Part IV: Theraputic opportunities for impaired bioenergetics 15. Targeting Alzheimer's disease neuronal mitochondria as a therapeutic approach 16. Mitochondria replacement as an innovative treatment to tackle impaired bioenergetics in clinical medicine 17. Mitochondrial drug delivery systems: therapeutic application for clinical bioenergetics in neurodegenerative disease 18. Dietary interventions for patients with obesity and impaired bioenergetics 19. Novel nutraceuticals to tackle brain and muscle bioenergetics 20. Therapeutic targeting of cardiolipin composition in injury and disease using TPP-conjugated compounds 21. NEET proteins as novel drug targets for mitochondrial dysfunction 22. Translation of bioenergetics therapies: challenges from bench to bedside 23. New therapeutics to modulate mitochondrial energy metabolism in neurodegenerative disorders: the example of mitochondrial disorders 24. Targeting impaired bioenergetics in heart failure 25. Exploring vulnerabilities of quiescent tumor cells by targeting mitochondrial bioenergetics 26. Modulation of the mitochondrial function with polyphenols and other natural bioactive compounds to treat obesity 27. Antioxidants and natural-derived products in the modulation of mitochondrial bioenergetics and dysfunction in chronic kidney disease models 28. Transcranial and systemic photobiomodulation for the enhancement of mitochondrial metabolism in depression 29. Alterations in mitochondrial glucose carbon metabolism in epilepsy and targeted metabolic treatments

Authors

Sergej M. Ostojic Sergej M. Ostojic, Department of Nutrition and Public Health, University of Agder, Kristiansand, Norway. Dr. Sergej M. Ostojic is a full professor of nutrition at the University of Agder and the University of Novi Sad. His current research follows two main themes: studying mitochondrial viability and targeted nutritional interventions to tackle impaired bioenergetics in health and disease, and analyzing population health metrics in chronic cardiometabolic diseases. To date, he has authored and coauthored over 280 peer-reviewed research and review articles in high-impact journals, such as The Lancet, Nature, The BMJ, Trends in Food Science and Technology, Trends in Endocrinology and Metabolism, Advances in Nutrition, Mayo Clinic Proceedings, Clinical Nutrition, Pharmacological Research, Nutrients, European Journal of Nutrition, and Nutritional Neuroscience. He is a member of the American College of Physicians, the American Society for Nutrition, the American Physiological Society, the International Society for Cerebral Blood Flow and Metabolism, and the Nutrition Society, and has been the recipient of internationally competitive research grants including the WADA Scientific Research Grant, NSCA International Award, and the European Commission, and many industrial endowments. Dr. Ostojic holds eight patents and patent applications in the United States, United Kingdom, European Union, and Japan.